123 related articles for article (PubMed ID: 37257580)
21. Actual Anti-TNF Trough Levels Relate to Serum IL-10 in Drug-Responding Patients With Crohn's Disease.
Zapater P; Almenara S; Gutiérrez A; Sempere L; García M; Laveda R; Martínez A; Scharl M; Cameo JI; Linares R; González-Navajas JM; Wiest R; Rogler G; Francés R
Inflamm Bowel Dis; 2019 Jul; 25(8):1357-1366. PubMed ID: 30776076
[TBL] [Abstract][Full Text] [Related]
22. Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial.
Colombel JF; Panaccione R; Bossuyt P; Lukas M; Baert F; Vaňásek T; Danalioglu A; Novacek G; Armuzzi A; Hébuterne X; Travis S; Danese S; Reinisch W; Sandborn WJ; Rutgeerts P; Hommes D; Schreiber S; Neimark E; Huang B; Zhou Q; Mendez P; Petersson J; Wallace K; Robinson AM; Thakkar RB; D'Haens G
Lancet; 2017 Dec; 390(10114):2779-2789. PubMed ID: 29096949
[TBL] [Abstract][Full Text] [Related]
23. Safety and efficacy of BI 695501 versus adalimumab reference product in patients with advanced Crohn's disease (VOLTAIRE-CD): a multicentre, randomised, double-blind, phase 3 trial.
Hanauer S; Liedert B; Balser S; Brockstedt E; Moschetti V; Schreiber S
Lancet Gastroenterol Hepatol; 2021 Oct; 6(10):816-825. PubMed ID: 34388360
[TBL] [Abstract][Full Text] [Related]
24. Clinical features and monocyte/macrophage subsets characterization in granulomatous vs non-granulomatous Crohn's disease.
Zhao L; Tang Y; Lei N; Zhou D; Chen B; Gan T; Yang X; Zhang Y
Scand J Gastroenterol; 2020 Apr; 55(4):442-448. PubMed ID: 32285715
[No Abstract] [Full Text] [Related]
25. Influence of polymorphisms and TNF and IL1β serum concentration on the infliximab response in Crohn's disease and ulcerative colitis.
Lacruz-Guzmán D; Torres-Moreno D; Pedrero F; Romero-Cara P; García-Tercero I; Trujillo-Santos J; Conesa-Zamora P
Eur J Clin Pharmacol; 2013 Mar; 69(3):431-8. PubMed ID: 22960943
[TBL] [Abstract][Full Text] [Related]
26. Magnetic resonance enterography changes after antibody to tumor necrosis factor (anti-TNF) alpha therapy in Crohn's disease: correlation with SES-CD and clinical-biological markers.
Stoppino LP; Della Valle N; Rizzi S; Cleopazzo E; Centola A; Iamele D; Bristogiannis C; Stoppino G; Vinci R; Macarini L
BMC Med Imaging; 2016 May; 16(1):37. PubMed ID: 27149857
[TBL] [Abstract][Full Text] [Related]
27. Ex vivo inhibited cytokine profiling may explain inferior treatment response to golimumab after adalimumab failure in rheumatoid arthritis.
Tweehuysen L; Schraa K; Netea MG; van den Hoogen FHJ; Joosten LAB; den Broeder AA
Clin Exp Rheumatol; 2018; 36(1):140-143. PubMed ID: 29148425
[TBL] [Abstract][Full Text] [Related]
28. A BET Protein Inhibitor Targeting Mononuclear Myeloid Cells Affects Specific Inflammatory Mediators and Pathways in Crohn's Disease.
Elfiky AMI; Hageman IL; Becker MAJ; Verhoeff J; Li Yim AYF; Joustra VW; Mulders L; Fung I; Rioja I; Prinjha RK; Smithers NN; Furze RC; Mander PK; Bell MJ; Buskens CJ; D'Haens GR; Wildenberg ME; de Jonge WJ
Cells; 2022 Sep; 11(18):. PubMed ID: 36139421
[TBL] [Abstract][Full Text] [Related]
29. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.
Magro F; Portela F
BioDrugs; 2010 Dec; 24 Suppl 1():3-14. PubMed ID: 21175228
[TBL] [Abstract][Full Text] [Related]
30. Adalimumab as second line anti-tumour necrosis factor alpha therapy for Crohn's disease: A single centre experience.
Sprakes MB; Hamlin PJ; Warren L; Greer D; Ford AC
J Crohns Colitis; 2011 Aug; 5(4):324-31. PubMed ID: 21683302
[TBL] [Abstract][Full Text] [Related]
31. [Role of Rac1 signaling pathway of azathioprine and peptidoglycan in the regulation of monocyte-macrophage apoptosis in Crohn's disease].
Zhou Z; Jing Y; Ran Y; Zhao J; Zhou L; Wang BM
Zhonghua Nei Ke Za Zhi; 2018 Apr; 57(4):279-284. PubMed ID: 29614587
[No Abstract] [Full Text] [Related]
32. Transferrin Level Before Treatment and Genetic Polymorphism in HFE Gene as Predictive Markers for Response to Adalimumab in Crohn's Disease Patients.
Repnik K; Koder S; Skok P; Ferkolj I; Potočnik U
Biochem Genet; 2016 Aug; 54(4):476-486. PubMed ID: 27115882
[TBL] [Abstract][Full Text] [Related]
33. Circulating miR-125a but not miR-125b is decreased in active disease status and negatively correlates with disease severity as well as inflammatory cytokines in patients with Crohn's disease.
Sun CM; Wu J; Zhang H; Shi G; Chen ZT
World J Gastroenterol; 2017 Nov; 23(44):7888-7898. PubMed ID: 29209130
[TBL] [Abstract][Full Text] [Related]
34. Monocytes from infliximab-resistant patients with Crohn's disease exhibit a disordered cytokine profile.
Gaiani F; Rotoli BM; Ferrari F; Barilli A; Visigalli R; Carra MC; de'Angelis GL; de'Angelis N; Dall'Asta V
Sci Rep; 2020 Jul; 10(1):12238. PubMed ID: 32699266
[TBL] [Abstract][Full Text] [Related]
35. Comparison of two adalimumab treatment schedule strategies for moderate-to-severe Crohn's disease: results from the CHARM trial.
Colombel JF; Sandborn WJ; Rutgeerts P; Kamm MA; Yu AP; Wu EQ; Pollack PF; Lomax KG; Chao J; Mulani PM
Am J Gastroenterol; 2009 May; 104(5):1170-9. PubMed ID: 19352339
[TBL] [Abstract][Full Text] [Related]
36. Adalimumab in pediatric Crohn's disease.
Patel AS; Suarez LD; Rosh JR
Immunotherapy; 2016 Feb; 8(2):127-33. PubMed ID: 26787222
[TBL] [Abstract][Full Text] [Related]
37. Anti-Tumor Necrosis Factor With a Glyco-Engineered Fc-Region Has Increased Efficacy in Mice With Colitis.
Bloemendaal FM; Levin AD; Wildenberg ME; Koelink PJ; McRae BL; Salfeld J; Lum J; van der Neut Kolfschoten M; Claassens JW; Visser R; Bentlage A; D'Haens GRAM; Verbeek JS; Vidarsson G; van den Brink GR
Gastroenterology; 2017 Nov; 153(5):1351-1362.e4. PubMed ID: 28756234
[TBL] [Abstract][Full Text] [Related]
38. Serological Biomarkers of Tissue Turnover Identify Responders to Anti-TNF Therapy in Crohn's Disease: A Pilot Study.
van Haaften WT; Mortensen JH; Dige AK; Grønbæk H; Hvas CL; Bay-Jensen AC; Karsdal MA; Olinga P; Manon-Jensen T; Dijkstra G
Clin Transl Gastroenterol; 2020 Sep; 11(9):e00217. PubMed ID: 33094957
[TBL] [Abstract][Full Text] [Related]
39. Increased Expression of Interleukin-13 Receptor in Ileum Associated With Nonresponse to Adalimumab in Ileal Crohn's Disease.
Wong ECL; Yusuf A; Pokryszka J; Dulai PS; Colombel JF; Marshall JK; Reinisch W; Narula N
Inflamm Bowel Dis; 2023 Jun; 29(6):875-882. PubMed ID: 35880680
[TBL] [Abstract][Full Text] [Related]
40. Immunoregulatory properties of IL-13 in patients with inflammatory bowel disease; comparison with IL-4 and IL-10.
Kucharzik T; Lügering N; Weigelt H; Adolf M; Domschke W; Stoll R
Clin Exp Immunol; 1996 Jun; 104(3):483-90. PubMed ID: 9099934
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
